Adial Pharmaceuticals Inc... (ADIL)
Adial Pharmaceuticals Statistics
Share Statistics
Adial Pharmaceuticals has 6.47M shares outstanding. The number of shares has increased by 289.23% in one year.
| Shares Outstanding | 6.47M |
| Shares Change (YoY) | 289.23% |
| Shares Change (QoQ) | 1.11% |
| Owned by Institutions (%) | 8.52% |
| Shares Floating | 6.36M |
| Failed to Deliver (FTD) Shares | 13.68K |
| FTD / Avg. Volume | 1.56% |
Short Selling Information
The latest short interest is 78.88K, so 1.22% of the outstanding shares have been sold short.
| Short Interest | 78.88K |
| Short % of Shares Out | 1.22% |
| Short % of Float | 1.24% |
| Short Ratio (days to cover) | 0.65 |
Valuation Ratios
The PE ratio is -0.38 and the forward PE ratio is -0.59. Adial Pharmaceuticals's PEG ratio is 0.01.
| PE Ratio | -0.38 |
| Forward PE | -0.59 |
| PS Ratio | 0 |
| Forward PS | 0.2 |
| PB Ratio | 0.65 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0.01 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Adial Pharmaceuticals Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.9, with a Debt / Equity ratio of 0.
| Current Ratio | 4.9 |
| Quick Ratio | 4.9 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.71% and return on capital (ROIC) is -168.68%.
| Return on Equity (ROE) | -1.71% |
| Return on Assets (ROA) | -1.48% |
| Return on Capital (ROIC) | -168.68% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1,750,472.5 |
| Employee Count | 4 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -76.38% in the last 52 weeks. The beta is 1.18, so Adial Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.18 |
| 52-Week Price Change | -76.38% |
| 50-Day Moving Average | 0.93 |
| 200-Day Moving Average | 1.05 |
| Relative Strength Index (RSI) | 44.55 |
| Average Volume (20 Days) | 874.74K |
Income Statement
| Revenue | n/a |
| Gross Profit | -564 |
| Operating Income | -6.89M |
| Net Income | -7M |
| EBITDA | -7M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -5.44 |
Balance Sheet
The company has 2.83M in cash and 0 in debt, giving a net cash position of 2.83M.
| Cash & Cash Equivalents | 2.83M |
| Total Debt | 0 |
| Net Cash | 2.83M |
| Retained Earnings | -68.8M |
| Total Assets | 6.71M |
| Working Capital | 4.79M |
Cash Flow
In the last 12 months, operating cash flow was -6.81M and capital expenditures 6.81M, giving a free cash flow of 0.
| Operating Cash Flow | -6.81M |
| Capital Expenditures | 6.81M |
| Free Cash Flow | 0 |
| FCF Per Share | 0 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ADIL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -706.49% |
| FCF Yield | 0% |
Analyst Forecast
The average price target for ADIL is $8, which is 939% higher than the current price. The consensus rating is "Buy".
| Price Target | $8 |
| Price Target Difference | 939% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Aug 7, 2023. It was a backward split with a ratio of 1:25.
| Last Split Date | Aug 7, 2023 |
| Split Type | backward |
| Split Ratio | 1:25 |
Scores
| Altman Z-Score | -15.97 |
| Piotroski F-Score | 3 |